Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Lexeo Therapeutics (LXEO), 3,022% surge in interest
• Dominari Holdings (DOMH), 81% surge in interest
• Galecto (GLTO), 60% surge in interest
• Catalyst Pharmaceuticals (CPRX), 53% surge in interest
• Tonix Pharmaceuticals (TNXP), 39% surge in interest

Pipeline and key clinical candidates for these companies:

Lexeo Therapeutics is a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia cardiomyopathy, LX2020 for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.

Dominari Holdings is a holding company that, through its various subsidiaries, is currently engaged in wealth management, investment banking, sales and trading and asset management. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. In addition to organic growth, the company seeks opportunities outside of its current business to enhance stockholder value, including in the AI and Data Center sector.

Galecto is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 for multiple genetic subsets of AML; an orally active galectin-3 inhibitor in combination with a checkpoint inhibitor for various oncology indications; and an orally active galectin-3 inhibitor for the treatment of liver cirrhosis.

Catalyst says it is “committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases”. Catalyst’s flagship U.S. commercial product is Firdapse tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome for adults and for children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights to Fycompa CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia. The FDA has accepted the NDA filing for TNX-102 SL for fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense.

Recent news on these stocks:

March 24

Lexeo Therapeutics reported Q4 earnings per share that was in line with consensus estimates. “We are pleased to share further regulatory clarity for LX2006 for the treatment of Friedreich ataxia cardiomyopathy, and we appreciate the continued partnership from the FDA on an accelerated approval pathway to support adults and children living with this devastating condition,” said R. Nolan Townsend, CEO. “We are also encouraged by the favorable safety profile and early data observed in participants dosed with LX2020 to date. We look forward to sharing additional clinical updates later in 2025 now that the second cohort of the LX2020 HEROIC-PKP2 Phase 1/2 trial in arrhythmogenic cardiomyopathy is fully enrolled.”

Tonix Pharmaceuticals announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the Company’s New Drug Application for TNX-102 SL for the management of fibromyalgia. If approved, TNX-102 SL would be the first new treatment option for fibromyalgia patients in 15 years. The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.